Work

“Companion Diagnostics”: Has Their Time Come and Gone?

Year: 2014

Type: article

Abstract: Rapid development of molecularly targeted drugs requires a "companion diagnostic" that could delay drug development and limit availability of active drugs for relevant patients. Were the negative results from MetMab studies in patients with advanced non-small cell lung cancer due to drug failure or failure of the right companion diagnostic?

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-14-0932

Authors: Fred R. Hirsch, Paul A. Bunn, Roy S. Herbst

Institutions: University of Colorado Cancer Center, Yale University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute, National Center for Advancing Translational Sciences